BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10206011)

  • 21. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
    Mihou D; Katodritou E; Zervas K
    Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors in multiple myeloma: a new staging system based on clinical and morphological features.
    Pasqualetti P; Casale R; Collacciani A; Colantonio D
    Eur J Cancer; 1991; 27(9):1123-6. PubMed ID: 1835621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
    Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
    Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA-image cytometry and clinical staging systems in multiple myeloma.
    Kropff M; Leo E; Steinfurth G; Esselborn H; Adler CP; Böcking A
    Anticancer Res; 1994; 14(5B):2183-8. PubMed ID: 7840520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?
    Filonzi G; Mancuso K; Zamagni E; Nanni C; Spinnato P; Cavo M; Fanti S; Salizzoni E; Bazzocchi A
    AJR Am J Roentgenol; 2017 Jul; 209(1):152-158. PubMed ID: 28418695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system.
    Durie BG
    Eur J Cancer; 2006 Jul; 42(11):1539-43. PubMed ID: 16777405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of stratification systems in multiple myeloma. II. Clinical staging systems.
    Scudla V; Indrák K
    Neoplasma; 1985; 32(4):481-93. PubMed ID: 4047259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical considerations on a comparative study of two staging systems for multiple myeloma.
    Merlini G; Jayakar D
    Nouv Rev Fr Hematol (1978); 1984; 26(6):397-400. PubMed ID: 6527945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
    Kim H; Sohn HJ; Kim S; Kim K; Lee JH; Bang SM; Kim DH; Sohn SK; Lee JJ; Suh C
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):837-44. PubMed ID: 16864054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic variables and clinical staging in multiple myeloma.
    Cavo M; Galieni P; Zuffa E; Baccarani M; Gobbi M; Tura S
    Blood; 1989 Oct; 74(5):1774-80. PubMed ID: 2790201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognosis of multiple myeloma treated with conventional chemotherapy has not improved in 20 years].
    Dubost JJ; Ristori JM; Soubrier M; Zbadi K; Bussière JL; Sauvezie B
    Rev Med Interne; 1996; 17(11):895-900. PubMed ID: 8977970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone.
    Baldini L; Radaelli F; Chiorboli O; Fumagalli S; Cro L; Segala M; Cesana BM; Polli EE; Maiolo AT
    Cancer; 1991 Jul; 68(1):62-7. PubMed ID: 2049754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems.
    Fechtner K; Hillengass J; Delorme S; Heiss C; Neben K; Goldschmidt H; Kauczor HU; Weber MA
    Radiology; 2010 Oct; 257(1):195-204. PubMed ID: 20851941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors and therapeutic results in multiple myeloma.
    Nagai M; Kitahara T; Minato K; Takenaka T; Konda C; Seki S; Shimoyama M
    Jpn J Clin Oncol; 1985 Sep; 15(3):505-15. PubMed ID: 4057632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of two staging systems for myeloma.
    Vercelli D; Cozzolino F; Di Guglielmo R
    Nouv Rev Fr Hematol (1978); 1981; 23(2):107-10. PubMed ID: 7290984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of five staging systems in 470 patients with multiple myeloma.
    Mihou D; Katodritou I; Zervas K
    Haematologica; 2006 Aug; 91(8):1149-50. PubMed ID: 16885059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Staging of myeloma. A preliminary study of staging factors and treatment in different stages.
    Osby E; Carlmark B; Reizenstein P
    Recent Results Cancer Res; 1978; 65():21-7. PubMed ID: 106448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical study of multiple myeloma: a report of 182 cases].
    Xu L; Wang Y; Wu W; Yan H; Gao XD; Yu Q; Shen ZX; Mi JQ
    Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):972-7. PubMed ID: 20646647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison among immunologically different subtypes of 595 untreated multiple myeloma patients in northern China.
    Zhang L; Qi JY; Qi PJ; Wang YF; Zou DH; Yao HJ; An G; Yi SH; Li Q; Qiu LG
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):197-204. PubMed ID: 20511165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.